We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shire's New Formulation of Oncaspar Gets Approval in Europe
Read MoreHide Full Article
Shire plc announced that the European Commission (“EC”) has granted marketing authorization to its new freeze-dried formulation of Oncaspar for treating acute lymphoblastic leukemia ("ALL") in Europe. The new lyophilized formulation is approved as a component of a multi-agent chemotherapeutic regimen in pediatric patients (from birth to 18 years) as well as adult patients.
The approval in EU was expected as the drug was recommended by the Committee for Medicinal Products for Human Use (“CHMP”) in October. Presently, the drug is approved in liquid form for treating the same indication. The approval of the new formulation will increase the shelf life of Oncaspar up to three times to 24 months.
Shire’s shares have underperformed the industry so far this year. The company’s shares have lost 13.8% against the industry’s gain of 6.2%.
The CHMP had recommended the approval of the new formulation based on analytical and nonclinical studies, which showed that lyophilized Oncaspar has comparable efficacy to the liquid formulation.
The formulation is now approved in all 28 European Union ("EU") member countries plus Iceland, Norway and Liechtenstein.
Lyophilized Oncaspar works in a similar way as liquid Oncaspar and has the same dosing regimen as well.
Shire’s oncology segment witnessed growth of 24% in the third quarter of 2017 driven by strong sales of Oncaspar and pancreatic cancer drug, Onivyde. The increase in shelf life with this new formulation is expected to help the company improve the supply of this critical drug. Moreover, the new formulation will improve the accessibility of the drug to ALL patients in countries where the liquid form is not allowed.
The company expects the new formulation of Oncaspar to be available in Europe in the first half of 2018.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company’s shares have returned 3.8% so far this year.
Corcept’s earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company’s stock is up 138.1% so far this year.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
Shire's New Formulation of Oncaspar Gets Approval in Europe
Shire plc announced that the European Commission (“EC”) has granted marketing authorization to its new freeze-dried formulation of Oncaspar for treating acute lymphoblastic leukemia ("ALL") in Europe. The new lyophilized formulation is approved as a component of a multi-agent chemotherapeutic regimen in pediatric patients (from birth to 18 years) as well as adult patients.
The approval in EU was expected as the drug was recommended by the Committee for Medicinal Products for Human Use (“CHMP”) in October. Presently, the drug is approved in liquid form for treating the same indication. The approval of the new formulation will increase the shelf life of Oncaspar up to three times to 24 months.
Shire’s shares have underperformed the industry so far this year. The company’s shares have lost 13.8% against the industry’s gain of 6.2%.
The CHMP had recommended the approval of the new formulation based on analytical and nonclinical studies, which showed that lyophilized Oncaspar has comparable efficacy to the liquid formulation.
The formulation is now approved in all 28 European Union ("EU") member countries plus Iceland, Norway and Liechtenstein.
Lyophilized Oncaspar works in a similar way as liquid Oncaspar and has the same dosing regimen as well.
Shire’s oncology segment witnessed growth of 24% in the third quarter of 2017 driven by strong sales of Oncaspar and pancreatic cancer drug, Onivyde. The increase in shelf life with this new formulation is expected to help the company improve the supply of this critical drug. Moreover, the new formulation will improve the accessibility of the drug to ALL patients in countries where the liquid form is not allowed.
The company expects the new formulation of Oncaspar to be available in Europe in the first half of 2018.
Shire PLC Price
Shire PLC Price | Shire PLC Quote
Zacks Rank & Stocks to Consider
Shire carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. (CLDX - Free Report) , ACADIA Pharmaceuticals Inc. (ACAD - Free Report) and Corcept Therapeutics Inc. (CORT - Free Report) . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Celldex’s loss estimates narrowed from $1.03 to 93 cents for 2017 and from 96 cents to 90 cents over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 15.36%.
ACADIA’s loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 9.95%. The company’s shares have returned 3.8% so far this year.
Corcept’s earnings per share estimates have increased from 78 cents to 88 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters with an average beat of 14.32%. The company’s stock is up 138.1% so far this year.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>